Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) secured orphan drug status from the European Commission for imsidolimab in generalized pustular psoriasis, a designation providing key regulatory and market incentives in the EU.
Biomea Fusion, Inc. (NASDAQ: BMEA) shares closed up 16% at $1.59 after the company completed target enrollment of 64 participants for the Phase 2 COVALENT-211 study of icovamenib in individuals with insulin-deficient type 2 diabetes.
REGENXBIO Inc. (NASDAQ: RGNX) shares faced pressure as the FDA implemented a clinical hold on RGX-121 for MPS II following the discovery of asymptomatic spinal MRI findings in five CAMPSIITE subjects, a setback that postpones the BLA resubmission.
Biomea Fusion, Inc. (NASDAQ: BMEA) successfully finalized enrollment of 64 subjects for its Phase 2 COVALENT-211 trial evaluating icovamenib in insulin-deficient type 2 diabetes.
1. IRAN: Bessent Unveils "Operation Economic Outcast" as Oil Falls More Than 3%; China Vows to "Safeguard" Its Interests as Iran Claims It's "Fully Prepared"
● Zura Bio shares have jumped to $6.30, up 7.69%, on about 8.34 million shares traded, close to nine times the stock's average volume, marking real investor interest.
● Wetour Robotics shows a quoted advance to $27.59, up 6.07%, a price that sits uneasily against the company's own primary filings.
● Xenetic Biosciences shares have closed up 6.13% at $3.81, on about 102,790 shares changing hands, a small absolute figure but nearly five times the stock's recent norm.
● ZipRecruiter shares have climbed to $4.54, up 7.84%, with about 1.66 million shares changing hands and relativeVolumecomfortably above its recent average.
● Sono Group shares have gained to roughly $2.92, up 6.57%, but barely 9,200 shares traded, with relativeVolumeof about 0.04, essentially statistical noise for a company now worth only about $7 million.